Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Dr. Stefan Kertesz, PI of CSI: OPIOIDS

Dr. Stefan Kertesz is the principal investigator of CSI:OPIOIDs (Clinical Context of Suicide Following Opioid Transitions), a scientific research study that examines suicides after prescription opioid dose reductions in patients with long-term pain.

Beginning as a pilot study supported by UAB Heersink School of Medicine’s Department of Medicine, today it’s supported by a Veterans Administration grant under the title “CSI:OPIOIDs-V“.

The study’s purpose is to increase knowledge of the demographic, societal, and clinical factors that have led and may lead patients with pain to die by suicide after opioid reduction or stoppage.

A summary of the study can be found on its website.

To learn more about the study, select the following link.

To review the study’s summary sheet, select the following link.

Dr. Stefan Kertesz is certified in internal medicine and addiction medicine, has a 22-year history of delivering primary care for vulnerable populations such as the homeless, and an 18-year history of research funded by the National Institute on Drug Abuse and Veterans Administration on care and services for problems of addiction and drug use. An addiction scholar, Kertesz serves on multiple task forces and teams related to opioid safety. He also led a national petition that resulted in major changes to a planned policy set up by the Centers for Medicare and Medicaid Services.

#chronic #pain #addiction #patient #advocacy

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!